Clinical Trial Update: Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating regorafenib in combination with methotrexate for KRAS-mutated recurrent or metastatic non-small cell lung cancer has completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Regorafenib (regorafenib)

Snippet

Sponsor: Stanford University | Conditions: KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Status: COMPLETED | Results posted: 2023-08-01